Tokyo, July 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062259) titled 'Clinical Outcomes and Safety of Perioperative Durvalumab Plus Gemcitabine-Cisplatin Therapy for Muscle-Invasive Bladder Cancer: A Study at Shinshu University and Kagawa University' on July 16.
Study Type:
Observational
Primary Sponsor:
Institute - Shinshu University
Condition:
Condition - Muscle-Invasive Bladder Cancer (MIBC)
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the real-world effectiveness and safety of perioperative durvalumab plus GC therapy for muscle-invasive bladder cancer at Shinshu University and Kagawa University.
Basic objectiv...